Retrospective Study
Copyright ©The Author(s) 2021.
World J Hepatol. Jan 27, 2022; 14(1): 260-273
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.260
Table 3 The correlation of clinicopathologic factors and hepatitis B surface antigen expression patterns with viral replication in hepatitis B e antigen negative cases

HBV DNA
HAI
Fibrosis
Parameters
< 6.65
≥ 6.65
< 9
≥ 9
< 4
≥ 4
n233131233420
Age (yr)48.13 ± 10.3445.71 ± 12.0246.52 ± 11.7347.04 ± 10.9245.82 ± 11.6348.30 ± 10.81
Gender
Male10 (43.5)20 (64.5)19 (61.3)11 (47.8)23 (67.6)7 (35)a
Female13 (56.5)11 (35.5)12 (38.7)12 (52.2)11 (32.4)13 (65)
HBV DNA (log10IU/mL)--4.97 ± 1.497.56 ± 1.21a4.16 ± 0.973.98 ± 0.93
HBsAg (log10IU/mL)3.19 ± 0.843.92 ± 0.903.30 ± 0.83.86 ± 0.91a3.46 ± 0.954.03 ± 0.98
ALT IU/L96.09 ± 33.55163.06 ± 50.85a102.55 ± 41.36177.65 ± 80.65126.18 ± 64.87148.75 ± 58.6
ALT < 200 IU/L21 (91.3)18 (58.1)b26 (83.9)13 (56.5)a25 (73.5)14 (70)
ALT ≥ 200 IU/L2 (8.7)13 (41.9)5 (16.1)10 (43.5)9 (26.5)6 (30)
INR1.13 ± 0.271.17 ± 0.281.15 ± 0.31.16 ± 0.241.22 ± 0.321.04 ± 0.10b
Platelets (× 103/μL)234.91 ± 80.6216.31 ± 61.29237.67 ± 73.34206.64 ± 73.34218.21 ± 71.85236.5 ± 68.79
HAI score ≥ 92 (8.7)21 (67.7)b--14 (26.5)9 (70)b
HAI score < 921 (91.3)10 (32.3)--20 (73.5)11 (30)
Fibrosis ≥ 44 (17.4)16 (51.6)a6 (19.4)14 (60.9)b--
Fibrosis < 419 (82.6)15 (48.4) 25 (80.6)9 (39.1)--
p-HBsAg30.39 ± 14.1831.91 ± 14.0428.68 ± 11.1634.75 ± 16.7133.21 ± 15.3227.96 ± 10.93
HBsAg SP1
A6 (26.1)10 (32.3)13 (41.9)3 (13)a13 (38.2)3 (15)
B5 (21.7)9 (29)5 (16.1)9 (39.1)7 (20.6)7 (35)
C4 (17.4)1 (3.2)4 (12.9)1 (4.3)5 (14.7)0
D5 (21.7)1 (3.2)5 (16.1)1 (4.3)3 (8.8)3 (15)
E3 (13)10 (32.3)4 (12.9)9 (39.1)6 (17.6)7 (35)
HBsAg SP2
Diffuse11(47.8)19 (61.3)b18 (58.1)12 (52.2)a20 (58.8)10 (50)
Globular9 (39.1)2 (3.2)9 (29)1 (4.3)7 (20.6)3 (15)
Submembranous3 (13.1)10 (31.5)4 (12.9)10 (43.5)7 (20.6)7 (35)
Membranous expression
Present7 (30.4)13 (41.9)10 (32.3)10 (43.5)14 (41.2)6 (30)
Absent16 (69.6)18 (58.1)21 (67.7)13 (56.5)20 (58.8)14 (70)